The in vivo, liver-directed GT for the treatment of Transthyretin Amyloidosis, which is a fatal disease resulting from mutation to the TTR gene and is characterised by progressive accumulation of misfolded transthyretin (TTR) in different tissues. This evidence concerns the gene TTR and Familial transthyretin-related amyloidosis.